Fig. 1 · Structure

Documents & Downloads

DMP 777

Cat. No. A11390 CAS 157341-41-8

HLE inhibitor

DMP 777 is a potent, selective, and orally active human leukocyte elastase (HLE) inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

DMP 777 Research Summary

This section summarizes 4 in vivo studies of DMP 777 from 2 published references.

DMP 777 In Vivo Studies

In C57BL/6 mice, DMP 777 treatment significantly increased gastric FOXL1+/PDGFRα+/DAPI+ telocyte counts compared with untreated stomachs. Extended treatment reduced telocyte distribution at the top of the gland and increased their presence in the middle and basal regions. After 3 days of DMP 777 treatment, miR-148a was down-regulated in chief cells without GSII expression. After 10 days of treatment, miR-148a expression was significantly decreased. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Gastric Telocyte Counts Following Treatment

Animal study · Approximately 8 weeks C57BL/6 mice; n = 5 for Untreated and n = 4 for DMP-777 and L635 [1]

C57BL/6 mice received DMP 777 at 350 mg/kg by oral gavage once daily for up to 10 consecutive days. Treated stomachs showed a significant increase in FOXL1+/PDGFRα+/DAPI+ telocyte counts compared with untreated stomachs.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantification of telocyte countReported result a significant increase in the number of FOXL1+/PDGFRα+/DAPI+ telocytes in the stomachs treated with either DMP-777 or L635, compared with the untreated stomach[1]

Conditions shared by the study groups

Route
oral gavage
Treatment course
once a day for up to 10 consecutive days
Vehicle
1% methylcellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DMP 777 350 mg/kguntreated stomacha significant increase in the number of FOXL1+/PDGFRα+/DAPI+ telocytes in the stomachs treated with either DMP-777 or L635, compared with the untreated stomach[1]
DMP 777 350 mg/kg
Model: Approximately 8 weeks C57BL/6 mice; n = 5 for Untreated and n = 4 for DMP-777 and L635
Methods and source locations

Compound reported in the paper: DMP 777

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > FOXL1+/PDGFRα+ Double-Positive Telocytes Are Increased During Metaplasia Development in the Stomach (S23); Materials and Methods > Mice (S113, S114); Figure 2 legend (S172, S174)

Quantification of telocyte count: Quantification of telocyte count; comparator: untreated stomach — Results > FOXL1+/PDGFRα+ Double-Positive Telocytes Are Increased During Metaplasia Development in the Stomach (S23); Figure 2 legend (S172)

DMP 777 350 mg/kg · Results > FOXL1+/PDGFRα+ Double-Positive Telocytes Are Increased During Metaplasia Development in the Stomach (S23); Materials and Methods > Mice (S114)

Chief Cell miR-148a Following Treatment

Animal study · Eight-week-old C57BL/6 mice; 3 mice were used per group [2]

C57BL/6 mice received DMP 777 at 350 mg/kg by oral gavage once daily for 3 days. Fluorescence in situ hybridization showed down-regulation of miR-148a in chief cells without GSII expression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fluorescence in situ hybridization for miR-148aReported result miR-148a was down-regulated in chief cells without GSII expression after 3 days of DMP-777 treatment[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
once a day; 3 days
Vehicle
1% methylcellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DMP 777 350 mg/kgnormal chief cellsmiR-148a was down-regulated in chief cells without GSII expression after 3 days of DMP-777 treatment[2]
DMP 777 350 mg/kg
Model: Eight-week-old C57BL/6 mice; 3 mice were used per group
Methods and source locations

Compound reported in the paper: DMP 777

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S24); Materials and Methods > Mice (S60, S61, S62); Figure 3 legend (S157)

Fluorescence in situ hybridization for miR-148a: Fluorescence in situ hybridization for miR-148a; comparator: normal chief cells — Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S24); Figure 3 legend (S157)

DMP 777 350 mg/kg · Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S24); Materials and Methods > Mice (S62)

Telocyte Distribution Within Gastric Glands Following Treatment

Animal study · Approximately 8 weeks C57BL/6 mice; n = 4, except for DMP-777 3 Days, n = 3 [1]

C57BL/6 mice received DMP 777 at 350 mg/kg by oral gavage once daily, with telocyte distribution assessed after 1, 3, and 10 days. Extended treatment reduced telocyte distribution at the top and increased their presence in the middle and basal regions of the gland.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantification of telocyte distribution within the glandReported result Extended treatment with DMP-777 reduced telocyte distribution at the top and increased presence in the mid and base regions of the gland.[1]

Conditions shared by the study groups

Route
oral gavage
Treatment course
1, 3, and 10 days; once a day
Vehicle
1% methylcellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DMP 777 350 mg/kguntreated stomach tissueExtended treatment with DMP-777 reduced telocyte distribution at the top and increased presence in the mid and base regions of the gland.[1]
DMP 777 350 mg/kg
Model: Approximately 8 weeks C57BL/6 mice; n = 4, except for DMP-777 3 Days, n = 3
Methods and source locations

Compound reported in the paper: DMP 777

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Telocytes Show Altered Distribution Near the Expanding Proliferative Zone in DMP-777-Treated Mouse Stomach (S28, S29); Materials and Methods > Mice (S113, S114); Figure 3 legend (S184, S188, S189)

Quantification of telocyte distribution within the gland: Quantification of telocyte distribution within the gland; comparator: untreated stomach tissue — Figure 3 legend (S184, S188)

DMP 777 350 mg/kg · Results > Telocytes Show Altered Distribution Near the Expanding Proliferative Zone in DMP-777-Treated Mouse Stomach (S28); Materials and Methods > Mice (S114); Figure 3 legend (S188)

Chief Cell miR-148a Staining Following Extended Treatment

Animal study · Eight-week-old C57BL/6 mice; 3 mice were used per group [2]

C57BL/6 mice received DMP 777 at 350 mg/kg by oral gavage once daily for 10 days. Quantification of relative staining intensity showed significantly decreased miR-148a expression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantitation of relative miR-148a staining intensity in chief cells and transdifferentiating chief cells at the base of the glandReported result miR-148a expression was decreased significantly in mice with 10 days of DMP-777 treatment[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
once a day; 10 days
Vehicle
1% methylcellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DMP 777 350 mg/kgnormal chief cellsmiR-148a expression was decreased significantly in mice with 10 days of DMP-777 treatment[2]
DMP 777 350 mg/kg
Model: Eight-week-old C57BL/6 mice; 3 mice were used per group
Methods and source locations

Compound reported in the paper: DMP 777

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S23, S25); Materials and Methods > Mice (S60, S61, S62); Figure 3 legend (S158)

Quantitation of relative miR-148a staining intensity in chief cells and transdifferentiating chief cells at the base of the gland: Quantitation of relative miR-148a staining intensity in chief cells and transdifferentiating chief cells at the base of the gland; comparator: normal chief cells — Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S25); Figure 3 legend (S158)

DMP 777 350 mg/kg · Results > MiR-148a Expression in Mouse Stomach Assessed by In Situ Hybridization (S25); Materials and Methods > Mice (S62)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 157341-41-8
Applications HLE inhibitor
Formula C31H40N4O6
Molecular Weight 564.67
Synonyms L-694458
SMILES
CCC[C@H](C1=CC2=C(C=C1)OCO2)NC(N3[C@H](C(CC)(C3=O)CC)OC4=CC=C(C=C4)C(N5CCN(CC5)C)=O)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

DMP 777 Research References

  1. [1] Sohn Y, Flores Semyonov B, El-Mekkoussi H, et al. Telocyte Recruitment During the Emergence of a Metaplastic Niche in the Stomach. Cell Mol Gastroenterol Hepatol (2024). PMID: 38670488 DOI: 10.1016/j.jcmgh.2024.04.004 Source material
  2. [2] Shimizu T, Sohn Y, Choi E, et al. Decrease in MiR-148a Expression During Initiation of Chief Cell Transdifferentiation. Cell Mol Gastroenterol Hepatol (2020). PMID: 31473306 DOI: 10.1016/j.jcmgh.2019.08.008 Source material

Added to your cart

View Cart Checkout
Loading...